Skip to main content
Clinical Trials/CTRI/2017/11/010656
CTRI/2017/11/010656
Completed
Phase 2

Study of primary hypertension and therapeutic evaluation of sharbat aftimoon in its management.

ational Institute of Unani Medicine0 sites80 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
ational Institute of Unani Medicine
Enrollment
80
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 21, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ational Institute of Unani Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with stage\- 1 primary hypertension
  • ranging systolic pressure140 to 159 mmHg and
  • diastolic pressure 90 to 99 mmHg.
  • 2\.Patients who will agree to sign the informed
  • consent form and follow up the protocol.
  • 3\.Age group: 30 to 65 years.
  • 4\.Gender:Either

Exclusion Criteria

  • 1\.Patients with cardiac arrhythmias (chronic atrial
  • fibrillation, frequent premature ventricular and
  • atrial contractions, ventricular or
  • supraven¬tricular tachycardia, tachycardia \[heart
  • rate \> 100 beats per minute]), atrioventricular
  • 2\.Patients with malignant hypertension.
  • 3\.Patients with the episodes of marked arterial
  • hypotension (systolic BP \< 90 mmHg)
  • 4\.Patients with the history of myocardial
  • infarction or acute cerebrovascular events,

Outcomes

Primary Outcomes

Not specified

Similar Trials